

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2007 (13.12.2007)

PCT

(10) International Publication Number
WO 2007/140987 A1

(51) International Patent Classification:

A61K 31/4545 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/EP2007/004980

(22) International Filing Date:

5 June 2007 (05.06.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

874/MUM/06 7 June 2006 (07.06.2006) IN

(71) Applicant (for all designated States except US): SANDOZ

AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

AT, AU, AZ, BA, BB, BG, BI, BR, BW, BY, BZ, CA, CIL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): BHARATRAJAN, Ramaswami [IN/IN]; 86-B/12 Vrindavan Society, Thane (West) 400 601 (IN). TALASILA, Kamalakhar [IN/IN]; Flat N° 504, Tulip Wing-A, Maitri Garden Complex, Pokhran road N° 2, Thane (West) 400607, Maharashtra (IN).

(74) Agent: VON SPRECHER, Georg; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: STABLE AND BIOAVAILABLE FORMULATIONS AND A NOVEL FORM OF DESLORATADINE

(57) Abstract: An active pharmaceutical ingredient comprising 95% of form I of desloratadine and 5% of form II of desloratadine is disclosed. Also disclosed are a process for its preparation as well as a bioavailable and stable formulation containing this active pharmaceutical ingredient for the treatment of allergic diseases like allergic rhinitis, chronic idiopathic urticaria, asthma and other similar diseases. The compositions are formulated such as to provide protection to the drug from acidic excipients. The compositions of the present invention comprise desloratadine intimately mixed with hydrogenated vegetable oil and certain other excipients including acidic excipients.



WO 2007/140987 A1

STABLE AND BIOAVAILABLE FORMULATIONS AND A NOVEL FORM OF DESLORATADINE

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to Indian Provisional Application 874/MUM/2006, filed on June 7, 2006, and entitled "stable and bioavailable formulations and a novel form of desloratadine ", the contents of which are incorporated by reference herein.

FIELD OF THE INVENTION

The present invention pertains to an active pharmaceutical ingredient comprising desloratadine and to stable and bioavailable pharmaceutical compositions comprising desloratadine.

The oral dosage forms of the present invention are useful for treating patients exhibiting the allergic reactions associated with seasonal allergic rhinitis, perennial allergic rhinitis chronic idiopathic urticaria and other similar allergic conditions.

BACKGROUND OF THE INVENTION

Allergic diseases like allergic rhinitis, chronic idiopathic urticaria, asthma etc affect millions of people every year. Allergic rhinitis is of two types: seasonal allergic rhinitis and perennial allergic rhinitis. Seasonal allergic rhinitis is seasonal and is usually caused by pollen or mold, while perennial allergic rhinitis tends to be present for more than nine months of the year and can be attributed to dust mites, mold, animal dander or pollen in areas where high pollen counts are present for much of the year.

Chronic idiopathic urticaria is defined as the occurrence of wheals for duration of at least 6 weeks and is estimated to occur in 0.1 to 3% of the population. Its primary

manifestation is smooth, edematous wheals surrounded by red flare. The presence of wheals is accompanied by intense itching and is associated with high morbidity.

Histamine plays an important role in the pathophysiology of allergic diseases. This mediator is found in its highest concentration in lungs, mast cells and basophils. Exposure to a sensitizing allergen results in the attachment of IgE molecules to the cells causing release of histamine and other inflammatory mediators.

The action of histamine at the H-1 receptor produces the classic symptoms of an allergic response: pruritis, wheal and flare reactions of the skin; sneezing, nasal pruritus, rhinorrhoea, palatal pruritus, itchy, red and watery eyes and congestion in the nose. In more severe circumstances, mucous membranes of the ears and paranasal sinuses can be involved producing symptoms of ear fullness and popping, itchy throat and pressure in the area above the cheeks and forehead. Fatigue, weakness and malaise can also be present. Patients with allergic rhinitis may be limited in their ability to perform activities and often note disturbances in sleep, work performance, concentration and quality of life.

It is now considered crucial to optimally treat an individual with allergic rhinitis as chronic inflammation of the nasal mucosa and nasal obstruction, if left untreated, can lead to more serious conditions of the upper and lower airways including asthma, sinusitis, chronic otitis media with effusion, and nasal and sinus polyps.

Desloratadine is a selective, H₁-receptor antihistamine. It is the major orally active metabolite of loratadine and acts by selectively blocking histamine at the histamine H₁-receptor. *In vitro* it inhibits release of histamine from human mast cells. Mean peak plasma concentrations of desloratadine are reached within 3 hours. Neither food nor grapefruit juice has an effect on the bioavailability of desloratadine. It is metabolized to an active metabolite, 3-hydroxydesloratadine, which subsequently undergoes glucuronidation.

Desloratadine is, however, known to react to form a degradant, N-formyl desloratadine in tablet formulations. The formation of this N-formyl derivative is enhanced in the presence of acidic excipients such as silicon dioxide.

In general, tablet formulations require the presence of glidants. Silicon dioxide is the most widely used glidant in pharmaceuticals. Its small particle size and large specific surface area give it desirable flow characteristics that can be exploited to improve the flow properties of dry powders used in the tableting processes.

In order to avoid formulation of the N-formyl degradant prior art methods suggest addition of a pharmaceutically acceptable basic salt like calcium dibasic phosphate, preparation of a coated system, preparation of non-hygroscopic compositions or avoiding the use of reactive components to improve the shelf life of the desloratadine composition and prevent the degradation of desloratadine in the composition.

U.S. Patent 6,100,274 discloses a pharmaceutical composition for oral administration comprising an antiallergic effective amount of desloratadine in a pharmaceutically acceptable carrier medium comprising a desloratadine protective amount of a pharmaceutically acceptable basic salt and at least one pharmaceutically acceptable disintegrant.

The formulation of U.S. Patent 6,100,274 addresses the issue of the stability of desloratadine, which is sensitive to the effects of acidic excipients. The '274 patent teaches that it is therefore a requirement to use a pharmaceutically acceptable basic salt in the formulation while avoiding the use of any acidic excipients.

The pharmaceutical composition of US2002/123504 (the '504 application) comprises a therapeutically effective amount of desloratadine wherein the pharmaceutical composition is substantially free of reactive components like lactose and monosaccharide and disaccharides. The '504 application discloses instant release solid pharmaceutical dosage forms comprising an open matrix network carrying a therapeutically effective

amount of desloratadine or a pharmaceutically acceptable salt thereof, wherein the open matrix network comprises a carrier which does not interact with desloratadine. The '504 application discloses a composition in which active pharmaceutical ingredient is first granulated with an inert excipient, the resulting granules are coated with an inert or non-reactive coating agent, and finally the resulting coated granules blended with other excipients, including the reactive excipients. The '504 application further discloses a non-hygroscopic pharmaceutical composition comprising desloratadine or a pharmaceutically acceptable salt thereof, lactose and one or more pharmaceutically acceptable inert excipients, wherein the composition is substantially free of unbound water.

Accordingly, the '504 application deals with the issue of the instability of desloratadine and teaches that desloratadine reacts with lactose, resulting in a brown product. The '504 application further discloses a pharmaceutical composition not comprising such reactive components. Furthermore, the '504 application discloses the preparation of a non-hygroscopic composition, a coated composition or a matrix network to enhance the stability of the drug and reduce its degradation. It is therefore a requirement in the '504 application either to prepare a composition not comprising lactose or other similar reactive components, or to prepare a non-hygroscopic, coated or matrix composition to prevent the reaction of the desloratadine with the excipients.

The present invention provides a stable formulation of desloratadine that can be prepared without addition of a basic salt while still using silicon dioxide as glidant. Accordingly, the present invention has eliminated the use of a basic salt in combination with the active pharmaceutical ingredient while still using acidic components. The present invention has eliminated the need to prepare a non-hygroscopic or a coated composition to provide a stable and bioavailable desloratidine composition.

SUMMARY OF THE INVENTION

The present invention addresses the issue of the instability of desloratadine with certain excipients and provides a simple composition that doesn't require addition of a basic salt or the preparation of a coated or non-hygroscopic composition to prevent the discoloration and degradation of the drug in the presence of acidic components, but yet has desirable stability and bioavailability characteristics. Compositions of the present invention also possess good shelf life.

DETAILED DESCRIPTION OF THE INVENTION

Desloratadine has a high degree of therapeutic utility as some of the second-generation antihistamines were removed from the market because of their ability to block cardiac potassium channels resulting in the prolongation of the QT_c interval and development of torsades de pointes. No episode of QT prolongation or torsades de pointes associated with desloratadine was reported, but its degradation in the presence of certain excipients is a major problem because it reacts to form a degradant N-formyl desloratadine in tablet formulations. The formation of the N-formyl degradant was enhanced in the presence of acidic excipients like silicon dioxide.

Degradation of desloratadine is a major issue that not only affects the stability of the drug but also affects the bioavailability apart from the discolouration and degradation of the molecule. When a drug like desloratadine, which is susceptible to the effect of acidic components, is manufactured somewhat different formulations are required to be prepared so that it not only protects the drug from the effect of acidic excipients in a formulation but also provides a good release rate resulting in good bioavailability.

Desloratadine compositions are required for the management of certain allergic diseases. The present inventors have found that under the conventional method of preparing pharmaceutical dosage forms, desloratadine is not stable and forms degradant, N-formyl desloratadine in tablet formulations. Desloratadine contains an amine group in its structure and that has been found to react with conventional diluents such as lactose, resulting in a brown product. The present inventors have found that the presence of

several triglycerides of fatty acids, like hydrogenated cottonseed oil, reduces interactions of desloratadine with acidic excipients like silicon dioxide and other similar substances. The formulations of the present invention can be prepared by the conventional methods like wet granulation, direct compression and dry granulation.

The new preparations are stable to the effect of acidic components and prevent the discolouration and degradation of desloratadine while still providing bioavailability to marketed formulations. The compositions of the present invention were obtained by intimately mixing desloratadine with an inert carrier and possibly other excipients, followed by compressing the mixture into a tablet and finally coating with aqueous dispersions of opadry coating material.

For the purpose of the present invention, active pharmaceutical ingredient used to achieve desired tablet composition comprises 90-96% of form-I of desloratadine and 4-10% of form-II of desloratadine.

Desloratadine, microcrystalline cellulose, corn Starch, mannitol, and colloidal silicon dioxide were sifted and mixed. The blend (or mixture) was lubricated with hydrogenated cottonseed oil and compressed into tablets. The tablets were coated with an aqueous dispersion of opadry coating material.

The present invention provides an immediate release composition of desloratadine that effectively protects desloratadine while providing acceptable release and bioavailability.

The present invention provides an immediate release composition of desloratadine that is simple to manufacture and does not involve cost intensive methods of preparation.

The compositions of the present invention do not require the use of a pharmaceutically acceptable basic salt in combination with desloratadine and do not even require the preparation of a coated or a non-hygroscopic composition.

The present invention is therefore a simple and cost-effective solution to the stability and bioavailability problems of conventional desloratadine formulations. Interestingly, problems related to stability, discolouration and bioavailability of desloratadine are solved by the compositions of the present invention without the need of a pharmaceutically acceptable basic salt and without the use of a coated system or a non-hygroscopic composition.

Tablets prepared according to the present invention has eliminated the use of a pharmaceutically acceptable salt of basic compound and it also is not required to prepare a coated or a non-hygroscopic composition, while using acidic excipients in the composition. Those skilled in the art will appreciate that a stable and bioavailable formulation of desloratadine could be obtained even without adding a pharmaceutically acceptable basic salt or without even preparing a coated or non-hygroscopic or anhydrous composition.

While desloratadine is a preferred drug according to the present invention, other acid sensitive drugs are also included within the scope of the present invention.

The compositions of the present invention is comprise an inert carrier, like hydrogenated cottonseed oil, to prevent the interaction between the acid (or acid labile) sensitive drug (such as desloratadine) and acidic excipients. The inert carrier appears to act as a molecular barrier that limits interactions between the drug and the excipients.

Inert materials which are suitable for the present invention include, but are not limited to, hydrogenated cottonseed oil, hydrogenated soyabean oil and other hydrogenated vegetable oils-type-I.

It is contemplated within the scope of the invention that other inert materials like waxes and polyethylene glycols may also be used to prepare a molecular barrier.

"Immediate release" as defined herein refers to making an active ingredient available to the biological system of the host. An immediate release preparation according to the present invention is one that provides stability to the drug while not delaying release of the drug, thus providing good bioavailability.

"Acid-sensitive" as defined herein refers to a drug or any material that degrades in the presence of acidic excipients. An acid labile drug according to the present invention is one that degrades to an inactive derivative upon being exposed to an acidic environment.

"Inert carrier" according to the present invention is one that facilitates the creation of a molecular barrier and does not react with any other component of the compositions of the present invention. The inert carrier thus isolates the drug from acidic excipients thereby preventing interactions between drug (desloratadine) and the excipients, resulting in enhanced stability of the formulation.

"Therapeutically effective amount" according to the present invention is meant an amount of active pharmaceutical ingredient in the pharmaceutical compositions which is effective to beneficially treat histamine induced disorders. The term "therapeutically effective amount" as used herein indicates the amount of desloratadine required to be administered to a subject in need thereof, to have the desired therapeutic effect. In accordance with the present invention, desloratadine is preferably used in an amount ranging from about 0.1 mg to about 15 mg.

The immediate release compositions of the present invention employ certain other excipients that, although not essential for the present invention, are required for the formulation process as known to those skilled in art.

The compositions of the present invention typically include pharmaceutically acceptable excipients. It is well known that pharmaceutical excipients are routinely incorporated into solid dosage forms. This is done to ease the manufacturing process as well as to improve the performance of the dosage form. Common excipients include, but are not limited to diluents, lubricants, granulating aids, surfactants, pH adjusters, anti-adherents and

glidants *etc.* Such excipients may be routinely used in the dosage forms of the present invention.

If the desired formulation is a tablet, it may include one or more glidants, such as stearic acid, palmitic acid, talc, polyethylene glycol, colloidal silicon dioxide, carnauba wax and the like, and mixtures thereof. Other conventional pharmaceutical ingredients which may optionally be present include, but are not limited to, preservatives, stabilizers, and FD & C colours, *etc.*

The composition of the present invention may also comprise one or more of the following binders; corn starch, pregelatinized starch, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, gelatin, and hydroxy ethyl cellulose or other similar substances.

The composition of the present invention may also include one or more diluents such as microcrystalline cellulose, starch, pregelatinized starch, mannitol or other similar substances.

The composition of the present invention may also include one or more disintegrants, such as low substituted hydroxy propyl cellulose, sodium starch glycolate, crospovidone, croscarmellose sodium or other similar substances.

While this invention has been described in terms of specific embodiments, it should be understood that presented by way of illustration only and that the invention is not necessarily limited thereto. Modifications and variations within the spirit and scope of the claims that follow will be readily apparent from this disclosure as those skilled in the art will appreciate.

The following examples serve to illustrate the present invention without limiting it.

EXAMPLES

Example 1:

The immediate release oral pharmaceutical composition of the present invention was prepared as per the formula given in the Table 1 below. The example explains the use of acidic excipient colloidal silicon dioxide as glidant and hydrogenated cotton seed oil as lubricant as well as protecting agent.

Table 1

Sr.No	Ingredients	Quantity	
		mg per tablet	%w/w
1	Desloratadine	5	4.85
2	Microcrystalline cellulose(Avicel PH112)	61.3	59.51
3	Corn Starch(Purity 21A)	10	9.71
4	Mannitol(Pearlitol SD200)	21	20.39
5	Colloidal silicon dioxide(Aerosil 200)	1.5	1.46
6	Hydrogenated cottonseed oil(Sterotex NF)	1.2	1.17
7	Opadry coating material	3	2.91
8	Film coated tablet weight	103	100

Desloratadine, microcrystalline cellulose, corn starch, mannitol, and colloidal silicon dioxide were sifted and mixed. The blend was lubricated with hydrogenated cottonseed oil and compressed into tablets. The tablets were coated with aqueous dispersion of opadry coating material.

The tablets obtained were subjected to dissolution testing in 500 ml of 0.1N HCl using USP apparatus 2 (Paddles) at 50 rpm at 37±0.5°C. The results are presented in Table 2 below.

Table 2

Sr.No	Time (In minutes)	% Drug released
1	10	79
2	30	91
3	60	96

The tablets were subjected for stability studies. Results of the stability study are shown below in Table 3.

Table 3

Sr.No	Storage condition : 40°C/75%RH	Initial	1Month	1.5 Month
1	N-Formyl desloratadine impurity (%)	0.19	0.24	0.29
2	Total impurities (%)	0.19	0.35	0.34
3	Description	White to off white tablet	White to off white tablet	Whit to off white tablet

Example 2:

Table 4 shows the composition of desloratadine tablet according to the present invention.

Table 4

Sr.No	Ingredients	Quantity(mg per tablet)	Quantity(%w/w)
1	Desloratadine	5	4.85
2	Microcrystalline cellulose(Avicel PH112)	82.3	79.90
3	Corn Starch(Purity 21A)	10	9.71
4	Colloidal silicon dioxide(Aerosil 200)	1.5	1.46
5	Hydrogenated cottonseed oil(Sterotex NF)	1.2	1.17
6	Opadry coating material	3	2.91
7	Film coated tablet weight	103	100

Desloratadine, microcrystalline cellulose, corn starch and colloidal silicon dioxide were sifted and mixed. The blend was lubricated with sifted hydrogenated cottonseed oil and compressed into tablets. The tablets were coated with aqueous dispersions of opadry coating material.

The tablets obtained were subjected to dissolution testing in 500ml of 0.1N HCl using USP apparatus 2 (Paddles) at 50 rpm at 37±0.5°C.

The results are shown below in Table 5.

Table 5

Sr.No	Time(In minutes)	% Drug released
1	10	91
2	30	101
3	60	101

The tablets were subjected to stability studies. Results of the stability study are shown below in Table 6.

Table 6

Sr.No	Storage Conditions: 40°C/75%RH	Initial	1 Month
1	N-Formyl Desloratadine impurity (%)	0.09	0.09
2	Total Impurities (%)	0.09	0.17
3	Description	Whit to off white tablet	White to off white tablet

Example 3

Table 7 shows the composition of desloratadine tablet according to the present invention.

Table 7

Sr.No	Ingredients	Quantity	
		mg per tablet	%w/w
1	Desloratadine	5	4.85
2	Microcrystalline cellulose(Avicel PH112)	82.3	79.90
3	Pregelatinized Starch(Starch 1500 LM)	10	9.71
4	Colloidal silicon dioxide(Aerosil 200)	1.5	1.46
5	Hydrogenated cottonseed oil(Sterotex NF)	1.2	1.17
6	Opadry coating material	3	2.91
7	Film coated tablet weight	103	100

Desloratadine, microcrystalline cellulose, pregelatinized starch and colloidal silicon dioxide were sifted and mixed. The blend was lubricated with sifted hydrogenated cottonseed oil and compressed into tablets. The tablets were coated with aqueous dispersions of opadry coating material.

The tablets obtained were subjected to dissolution testing in 500ml of 0.1 N HCl using USP apparatus 2 (Paddles) at 50 rpm at $37 \pm 0.5^\circ\text{C}$.

The results are shown below in table 8.

Table 8

Sr.No	Time(in minutes)	% Drug released
1	10	96
2	30	100
3	60	100

The tablets were subjected to stability studies. Results of the stability study are shown below in table no 9.

Table 9

Sr.No	Storage Conditions: 40°C/75%RH	Initial	1 Month
1	N-Formyl Desloratadine impurity (%)	0.08	0.08
2	Total impurities (%)	0.13	0.13
3	Description	White to off white tablet	White to off white tablet

Example 4

Table 10 shows the composition of desloratadine tablet according to the present invention.

Table 10

Sr.No	Ingredients	Quantity	
		mg per tablet	%w/w
1	Desloratadine	5	4.85
2	Microcrystalline cellulose(Avicel PH101)	80.3	77.96
3	Corn Starch(Purity 21 A)	10	9.71
4	Hypromellose 6cps	2	1.94
5	Purified water	QS	QS
6	Colloidal silicon dioxide(Aerosil 200)	1.5	1.46
7	Hydrogenated cotton seed oil (Sterotex NF)	1.2	1.17
8	Opadry coating material	3	2.91
9	Film coated tablet weight	103	100

Desloratadine, microcrystalline cellulose, corn starch were sifted and mixed. A binder solution was prepared by dissolving hyperomellose in purified water. The dry mix was granulated with the binder solution. The wet granules were dried, sifted and milled. Sifted granules were lubricated with sifted colloidal silicon dioxide and hydrogenated cottonseed oil. The lubricated blend was compressed into tablets. The tablets were coated with an aqueous dispersion of opadry coating material.

The tablets obtained were subjected to dissolution testing in 500ml of 0.1 N HCl using USP apparatus 2(Paddles) at 50 rpm at $37 \pm 0.5^\circ\text{C}$.

The results are shown below in Table 11

Table 11

Sr.No	Time(in minutes)	% Drug released
1	10	80
2	30	92
3	60	102

Example 5

Table 12 shows the composition of desloratadine tablet according to the present invention.

Table 12

Sr.No	Ingredients	Quantity(mg per tablet)	Quantity (%w/w)
Inner Phase:			
1	Desloratadine	5.0	4.85
2	Microcrystalline cellulose(Avicel PH101)	80.3	77.96
3	Corn Starch(Purity 21 A)	10	9.71
4	Hyperomellose 6cps	2	1.94
5	Purified Water	QS	QS
Outer Phase			
6	Colloidal Silicon Dioxide(Aerosil 200)	1.5	1.46
7	Hydrogenated cotton seed oil(Sterotex NF)	1.2	1.17

Core Tablet Weight		100	97.09
8	Opadry coating material	3	2.91
Film coated tablet weight		103	100

Desloratadine, microcrystalline cellulose, corn starch were sifted and mixed. A binder solution was prepared by dissolving hyperomellose in purified water. The dry mix was granulated with the binder solution. The wet granules were dried, sifted and milled. Sifted granules were lubricated with sifted colloidal silicon dioxide and hydrogenated cottonseed oil. The lubricated blend was compressed into tablets. The tablets were coated with an aqueous dispersion of opadry coating material.

The tablets obtained were subjected to dissolution testing in 500ml of 0.1 N HCl using USP apparatus 2(Paddles) at 50rpm at $37 \pm 0.5^\circ\text{C}$.

The results are shown below in table 13.

Table 13

Sr.No	Time(in minutes)	%Drug Released
1	10	80
2	30	92
3	60	102

The tablets were subjected to stability studies. Results of the stability study are shown below in table 14.

Table 14

Sr.No	Storage Conditions: 40%C/75%RH	Initial	1 Month
1	N-Formyl desloratadine impurity (%)	0.11	0.11
2	Total impurities (%)	0.12	0.18
3	Description	White to off white tablet	White to off white tablet

Example 6

Table 15 shows the composition of desloratadine tablet according to the present invention.

Table 15

Sr.No	Ingredients	Quantity(in mg per tablet)	Quantity(in % w/w)
Inner Phase			
1	Microcrystalline Cellulose(Avicel PH 101)	77.3	75.05
2	Pregelatinized Starch(Starch 1500)	15.0	14.56
3	Colloidal Silicon dioxide(Aerosil 200)	1.5	1.46
Outer Phase			
4	Desloratadine	5.0	4.85
5	Hydrogenated cottonseed oil(Sterotex NF)	1.2	1.17
Core Tablet Weight		100	97.09
Film Coating			
6	Opadry Coating Material	3	2.91

Film Coated Tablet Weight	103	100
---------------------------	-----	-----

Microcrystalline cellulose, pregelatinized starch and colloidal Silicon dioxide were sifted and mixed. The dry mix was granulated with purified water. The wet granules were dried, sifted and milled. Sifted granules were blended with sifted desloratadine and lubricated with sifted hydrogenated cottonseed oil. The lubricated blend was compressed into tablets. The tablets were coated with an aqueous dispersion of opadry coating material.

The tablets obtained were subjected to dissolution testing in 500ml of 0.1N HCl using USP apparatus 2 (Paddles) at 50 rpm at 37±0.5°C.

The results are shown below in Table 16.

Table 16

Sr.No	Time(In minutes)	% Drug Released
1	10	79
2	30	94
3	60	98

The tablets were subjected for stability studies. Results of stability study are shown below in table 17.

Table 17

Sr.No	Storage Condition 40°C/75%RH	Initial	1 Month	2 Month
1	N-Formyl Desloratadine impurity (%)	0.16	0.21	0.27
2	Total impurities (%)	0.16	0.21	0.27
3	Description	White to off white tablet	White to off white tablet	White to off white tablet

CLAIMS

What is claimed is:

1. An active pharmaceutical ingredient comprising 90-96% of form I of desloratadine and 4-10% of form II of desloratadine.
2. The active pharmaceutical ingredient of claim 1 wherein form I of desloratadine is present in an amount ranging from 93-95% and form II of desloratadine is present in an amount ranging from 5-7%.
3. The active pharmaceutical ingredient of claim 1 comprising 95% of form I of desloratadine and 5% of form II of desloratadine.
4. A process for preparing the active pharmaceutical ingredient of claims 1, 2 or 3 comprising intimately mixing the form I of desloratadine with form II of desloratadine.
5. An immediate release pharmaceutical composition comprising 90-96% of form I of desloratadine or a pharmaceutically acceptable salt thereof and 4-10% of form II of desloratadine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
6. The pharmaceutical composition of claim 5 comprising 93-95% of form I of desloratadine or a pharmaceutically acceptable salt thereof and 5-7% of form II of desloratadine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
7. The pharmaceutical composition of claim 5 comprising 95% of form I of desloratadine or a pharmaceutically acceptable salt thereof and 5% of form II

of desloratadine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

8. The pharmaceutical composition of claim 5 wherein a therapeutically effective amount of desloratadine is 2.5 to 5 mg.
9. The pharmaceutical composition of claim 5 wherein a therapeutically effective amount of desloratadine is about 5 mg.
10. The pharmaceutical composition of claim 5 further comprising at least one acidic excipient.
11. The pharmaceutical composition of claim 5 wherein said pharmaceutically acceptable excipient is hydrogenated vegetable oil type-I, a wax or polyethylene glycol.
12. The pharmaceutical composition of claim 5 which is in the form of a capsule or a tablet.
13. The pharmaceutical composition of claim 12 which is in the form of a tablet.
14. A pharmaceutical composition which prevents degradation of desloratadine in the presence of acidic excipients comprising a therapeutically effective amount of desloratadine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
15. The pharmaceutical composition of claim 14 wherein said composition has a pH of about 3 to about 7.
16. The pharmaceutical composition of claim 14 wherein said composition has a pH of about 3 to about 5.

17. The pharmaceutical composition of claim 14 wherein said acidic excipient is colloidal silicon dioxide, sodium starch glycolate type B or low-substituted hydroxyl propyl cellulose.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2007/004980

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/4545 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2004/229896 A1 (TOTH ZOLTAN G [HU] ET AL) 18 November 2004 (2004-11-18) claim 1	1-17
A	US 2002/123504 A1 (REDMON MARTIN P [US] ET AL) 5 September 2002 (2002-09-05) cited in the application paragraph [0010]	1-17

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

10 October 2007

Date of mailing of the international search report

31/10/2007

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cattell, James

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/004980

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2004229896	A1	18-11-2004	US 2006135547 A1	22-06-2006
US 2002123504	A1	05-09-2002	NONE	